Frontlight ResearchEarly access
CompletedNo phase
Parabiotics Use with Nutritional Management in Pediatric Celiac Patients
Key facts
- Who runs it
- Ain Shams University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 30 people enrolled
- Started
- 12 Jul 2023
- Ended
- 20 Feb 2025
- Type of study
- Interventional
- Treatments tested
- Gluten free diet for 3 weeks then parabiotic (Lacteolfort®) for another 3 weeks
- Record updated
- 19 March 2025
Who can take part
- Age
- 2 years to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Celiac cases diagnosed either by non-biopsy approach {serology based: high IgA antibodies against transglutaminase ≥10 times the upper limit of normal with positive endomysial antibodies or diagnosed by biopsy using March classification
Who cannot take part
- Patients taking immunosuppressant drugs or antibiotics within the last 4 weeks or during the study
- Immunocompromised patients
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a sequential study to evaluate the effect of parabiotics as an adjuvant therapy with gluten restriction on quality of life in children with Celiac disease.
The group in the trial
- Pediatric celiac patientsTreatment being tested
Strict gluten free food regimen for 3 weeks then parabiotics (Lacteolfort ®) added for another 3 weeks.
Treatment: Gluten free diet for 3 weeks then parabiotic (Lacteolfort®) for another 3 weeks
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effect of Parabiotics As an Adjuvant in Nutritional Management of Pediatric Celiac Patients
- Record updated
- 19 March 2025